Last Updated: 12 Nov 2024
Executive Summary
Tempest Therapeutics Inc. (TPST) is a clinical-stage oncology company focused on developing targeted and immune-mediated small molecules for cancer treatment. The company's market capitalization is $27.48 million, and its latest stock price is $1.1. Analysts are bullish on TPST, with three strong buy ratings and three buy ratings. The analyst target price is $18.6, indicating significant potential upside.
Company Overview
Tempest Therapeutics is headquartered in South San Francisco, California. The company's pipeline includes several promising drug candidates in various stages of clinical development. TPST's lead candidate, TPST-1120, is a small molecule inhibitor of the c-MET receptor tyrosine kinase, which is being evaluated in a Phase 2 clinical trial for the treatment of non-small cell lung cancer.
Fundamental Analysis
Financially, TPST is still in the early stages of development and has yet to generate revenue. The company reported a net loss of $31.25 million in 2023, with an EPS of -$1.6. However, the company has a strong cash position of $107.6 million, which should provide it with sufficient runway to continue its clinical development programs.
Technical Analysis
Technically, TPST has been in a downtrend since its IPO in 2021. The stock is currently trading below its 50-day and 200-day moving averages, indicating short-term and long-term weakness. However, the stock has recently shown signs of bottoming, and a breakout above the $1.2 resistance level could signal a potential reversal.
Short Term Outlook
In the short term, TPST's stock price is likely to remain volatile as the company awaits clinical data from its ongoing trials. If the data is positive, the stock could rally significantly. However, if the data is negative, the stock could continue to decline.
Long Term Outlook
The long-term outlook for TPST is promising. The company has a strong pipeline of drug candidates, and its lead candidate, TPST-1120, has the potential to be a blockbuster drug. If TPST can successfully develop and commercialize its pipeline, the stock could have significant upside potential.
Analyst Recommendations
Analysts are bullish on TPST, with six out of six analysts recommending a buy or strong buy rating. The analyst target price of $18.6 implies a potential upside of over 1,600% from the current price.
